Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review

Contrasts With EMA Decision

Executive Summary

Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first

You may also be interested in...



Roche Hopes To Gain Broad Market For Tecentriq In Adjuvant NSCLC

An executive told Scrip the company hopes to target all-comers as well as PD-L1-positive patients.

Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy

The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda. 

Merck Cuts Pharma Revenue Guidance By $1.7bn Due To Pandemic

Overall, the pharma lowered its 2020 revenue guidance by $2.5bn at the midpoint, but also says it will save about $400m on SG&A expenses. Pandemic impacts expected mainly in Q2, normal resumption in Q4.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel